Terminated PHASE2 INTERVENTIONAL 2-arm NCT03241810

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)

Randomized Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)

Sponsor: Elevation Oncology

Conditions Metastatic Breast Cancer

Interventions Fulvestrant Placebo Seribantumab

Updated 19 times since 2017 Last updated: Aug 20, 2020 Started: Aug 15, 2017 Primary completion: Nov 30, 2018 Completion: Nov 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Merrimack Inc. terminated the trial early due to business decision

Other terminated trials from Elevation Oncology

More terminations from Elevation Oncology

Other Metastatic Breast Cancer trials with similar outcome

Browse all Metastatic Breast Cancer trials

A PHASE2 clinical study on Metastatic Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Elevation Oncology and has accumulated 19 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

19 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2

▶ Show 14 earlier versions

Dec 2021 — Dec 2022 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Oct 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2020 — Oct 2020 [monthly]

Terminated PHASE2
Dec 2019 — Jun 2020 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Oct 2018 — Dec 2019 [monthly]

Recruiting PHASE2
Aug 2018 — Oct 2018 [monthly]

Recruiting PHASE2
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Apr 2018 — May 2018 [monthly]

Recruiting PHASE2
Dec 2017 — Apr 2018 [monthly]

Recruiting PHASE2
Nov 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Oct 2017 — Nov 2017 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Aug 2017 — Oct 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Elevation Oncology

Data source: Elevation Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Antwerp, Belgium , Beverly Hills, United States , Bonn, Germany , Brussels, Belgium , Burlington, United States , Calgary, Canada , Chandler, United States , Chapel Hill, United States , Charlotte, United States and 45 more locations